| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 12, 2012Findings Published in The Journal of the American College of Cardiology Suggest Renal Denervation Could Substantially Reduce Cardiovascular Morbidity and Mortality for Patients with a Condition that Affects 120 Million People
MINNEAPOLIS - September 12, 2012 - Medtronic, Inc. (NYSE: MDT) today announced findings from a health-economic analysis published online before print in The Journal of the American College of...
-
Aug 27, 2012Low Mortality and Heart Failure Hospitalization Sustained at 5-Years Post Implant with Medtronic CRT-D Devices
MUNICH, GERMANY – August 27, 2012 – Medtronic, Inc. (NYSE: MDT) today announced findings from a new clinical analysis of the pivotal REVERSE (Resynchronization Reverse Remodeling in Systolic...
-
Aug 24, 2012Next-Generation Technology Reinforces Safety and Efficacy While Improving Procedure Efficiency
MINNEAPOLIS – Aug. 24, 2012 – Medtronic, Inc. (NYSE:MDT) today announced that its Arctic Front Advance™ Cardiac Cryoballoon has received both U.S. Food and Drug Administration (FDA) approval...
-
Aug 23, 2012
MINNEAPOLIS - August 23, 2012 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.26 per share of the company's common stock. The quarterly dividend...
-
Aug 21, 2012Revenue of $4.0 Billion Grew 5% on a Constant Currency Basis; 2% as Reported
MINNEAPOLIS - August 21, 2012 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2013, which ended July 27, 2012. The Company reported worldwide...
-
Jun 21, 2012Regulatory Agency Selects Investigational Medical Device for Endovascular Treatment of Thoracic Aortic Aneurysms Involving Branch Vessel for Early Feasibility Pilot Program
MINNEAPOLIS -- June 21, 2012 -- The U.S. Food and Drug Administration (FDA) recently selected a stent graft being developed by Medtronic, Inc. (NYSE: MDT) for an early feasibility pilot program...
-
Jun 21, 2012
MINNEAPOLIS - June 21, 2012 - The board of directors of Medtronic, Inc. (NYSE: MDT) today approved a 7.2 percent increase in its cash dividend for fiscal year 2013, raising the quarterly amount to...
-
Jun 8, 2012FDA to Review World's First Insulin Pump with Threshold Suspend - Another Significant Step Toward the Artificial Pancreas
MINNEAPOLIS - June 8, 2012 -In the next step toward the development of an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced that it has filed the final module of its Pre-Market...
-
May 31, 2012
MINNEAPOLIS--(BUSINESS WIRE)--May. 31, 2012-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Goldman Sachs 33rd Annual...
-
May 25, 2012Study Results Slated for Presentation in Late-Breaking Clinical Trials Session at Endocrinology Meeting Include Low Event Rates Through Two Years of Follow-Up
MINNEAPOLIS--(BUSINESS WIRE)--May. 25, 2012-- According to study results to be featured in Sunday’s late-breaking clinical trials session at the American Association of Clinical Endocrinologists...